While older anti-obesity drugs may lead to less weight loss than semaglutide and tirzepatide, they remain useful tools in ...

A majority with overweight/obesity discontinue within a year, but the rate is higher among those without type 2 diabetes.

Taking a compounded GLP-1 medication isn’t the same thing as your pharmacy filling a cheaper, generic version of the drug ...

GLP-1 medications have become popular for weight loss, and for good reason—they can help regulate appetite and support weight ...

What's the most attractive weight-loss stock right now? We asked Seeking Alpha analysts Edmund Ingham, Stephen Ayers and Oneil Trader for their picks. Read more here.

An hour of moderate-intensity exercise reduced sensations of hunger in people with overweight and obesity in a recent study.

A large cohort study examining more than 125,000 adults in the U.S. found that the majority of patients discontinue GLP-1 RA therapy within the first year, with those without Type 2 diabetes showing ...

Studies have suggested that GLP-1RAs may show promise for a host of conditions, from alcohol use disorder to Parkinson’s. But ...

Helix, a leader in precision health, is unveiling a new comprehensive clinico-genomic dataset of over 15,000 patients treated with glucagon-like-peptide-1 (GLP-1) agonists including semaglutide, ...

Nearly 2 in 3 people without diabetes quit popular weight loss drugs such as Ozempic or Victoza within one year, according to a new study.

Telehealth company Hims & Hers' first Super Bowl ad is provocative and effective in building awareness of its weight loss ...

Two surgeons told Becker's that, while weight loss medications show some promise for improving orthopedic procedures, we don't yet know enough about the long-term impact of these drugs.